The panel expressed concern that doctors were prescribing Low T drugs too broadly to middle-aged men who wanted to increase their libidos, according to FierceBiotech. The panel voted Wednesday to advise the FDA to limit the use of such drugs to a specific medical purpose.
Most of the panel wanted pricey cardiovascular tests to determine the risks in using Low T drugs for age-related problems rather than for specific medical issues. Four panel members thought that these studies should occur no matter the circumstances.
Repros has been trying to show its yet-to-be-approved drug Androxal is a safer alternative to market leader AndroGel. The company has focused its studies on an obese patients with sexual issues.RPRX data by YCharts